# Secukinumab Study in PSOriasis Exploring pruRITUS Intensity and Lesional Biomarkers

> **NCT02362789** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 132 (actual)

## Conditions studied

- Psoriasis

## Interventions

- **BIOLOGICAL:** Secukinumab
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT02362789
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-01-04
- **Primary completion:** 2016-07-15
- **Final completion:** 2016-07-15
- **Target enrollment:** 132 (ACTUAL)
- **Last updated:** 2018-12-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02362789

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02362789, "Secukinumab Study in PSOriasis Exploring pruRITUS Intensity and Lesional Biomarkers". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT02362789. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*